Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Kidney International

Volumn 89, Issue 1, 2016, Pages 28-39

  Macdougall, Iain C ^a   Bircher, Andreas J ^b   Eckardt, Kai Uwe ^c   Obrador, Gregorio T ^d   Pollock, Carol A ^e,f   Stenvinkel, Peter ^g   Swinkels, Dorine W ^h   Wanner, Christoph ⁱ   Weiss, Günter ^j   Chertow, Glenn M ^k   Adamson, John W ^l   Akizawa, Tadao ^l   Anker, Stefan D ^l   Auerbach, Michael ^l   Bárány, Peter ^l   Besarab, Anatole ^l   Bhandari, Sunil ^l   Cabantchik, Ioav ^l   Collins, Alan J ^l   Coyne, Daniel W ^l   De Francisco, Ángel L M ^l   Fishbane, Steven ^l   Gaillard, Carlo A J M ^l   Ganz, Tomas ^l   Goldsmith, David J ^l   Hershko, Chaim ^l   Jankowska, Ewa A ^l   Johansen, Kirsten L ^l   Kalantar Zadeh, Kamyar ^l   Kalra, Philip A ^l   Kasiske, Bertram L ^l   Locatelli, Francesco ^l   Małyszko, Jolanta ^l   Mayer, Gert ^l   McMahon, Lawrence P ^l   Mikhail, Ashraf ^l   Nemeth, Elizabeta ^l   Pai, Amy Barton ^l   Parfrey, Patrick S ^l   Pecoits Filho, Roberto ^l   Roger, Simon D ^l   Rostoker, Guy ^l   Rottembourg, Jacques ^l   Singh, Ajay K ^l   Slotki, Itzchak ^l   Spinowitz, Bruce S ^l   Tarng, Der Cherng ^l   Tentori, Francesca ^l   Toblli, Jorge E ^l   Tsukamoto, Yusuke ^l   Vaziri, Nosratola D ^l   Winkelmayer, Wolfgang C ^l   Wheeler, David C ^l   Zakharova, Elena ^l   more..

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSIDAD PANAMERICANA   (Mexico)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l NONE

more..

Author keywords

chronic kidney disease; hypersensitivity; infections; iron; overload; oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; FERRIC CARBOXYMALTOSE; FERRITIN; FERUMOXYTOL; HEPCIDIN; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; THIOCTIC ACID; TOCOPHEROL; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; HEMOGLOBIN;

ANAPHYLAXIS; ASYMPTOMATIC DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHEST TIGHTNESS; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; COUGHING; CYANOSIS; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; HEMODIALYSIS; HUMAN; HYPOTENSION; INFECTION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRIDOR; TACHYCARDIA; THORAX PAIN; UREMIA; URTICARIA; WHEEZING; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; HYPERSENSITIVITY; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

CARDIOVASCULAR DISEASES; FERRITINS; HEMATINICS; HEMOGLOBINS; HEPCIDINS; HUMANS; HYPERSENSITIVITY; INFECTION; IRON; IRON OVERLOAD; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84973130364     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2015.10.002     Document Type: Conference Paper

References (131)

1. A. Besarab, J.W. Kaiser, and S. Frinak A study of parenteral iron regimens in hemodialysis patients Am J Kidney Dis 34 1999 21 28
2. S.G. Rosenblatt, S. Drake, S. Fadem, and et al. Gastrointestinal blood loss in patients with chronic renal failure Am J Kidney Dis 1 1982 232 236
3. V. Wizemann, P. Buddensiek, J. de Boor, and et al. Gastrointestinal blood loss in patients undergoing maintenance dialysis Kidney Int Suppl 16 1983 S218 S220
4. J.A. Sargent, and S.R. Acchiardo Iron requirements in hemodialysis Blood Purif 22 2004 112 123
5. S. Flint, E. Taylor, J. Beavis, and et al. Increased iron requirement in hemodialysis patients on antiplatelet agents or warfarin Nephron Clin Pract 113 2009 c38 c45
6. R.M. Holden, G.J. Harman, M. Wang, and et al. Major bleeding in hemodialysis patients Clin J Am Soc Nephrol 3 2008 105 110
7. C.S. Landefeld, and L. Goldman Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy Am J Med 87 1989 144 152
8. S. Fishbane, E.A. Kowalski, L.J. Imbriano, and et al. The evaluation of iron status in hemodialysis patients J Am Soc Nephrol 7 1996 2654 2657
9. K. Kalantar-Zadeh, B. Hoffken, H. Wunsch, and et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era Am J Kidney Dis 26 1995 292 299
10. S. Stancu, L. Barsan, A. Stanciu, and et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 5 2010 409 416
11. N. Tessitore, G.P. Solero, G. Lippi, and et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin Nephrol Dial Transplant 16 2001 1416 1423
12. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Suppl 2 2012 279 335
13. N. Tessitore, D. Girelli, N. Campostrini, and et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents Nephrol Dial Transplant 25 2010 3996 4002
14. D.W. Swinkels, and J.F. Wetzels Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 23 2008 2450 2453
15. D.R. Ashby, D.P. Gale, M. Busbridge, and et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease Kidney Int 75 2009 976 981
16. K. van der Putten, K.E. Jie, D. van den Broek, and et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients Eur J Heart Fail 12 2010 943 950
17. N.C. van der Weerd, M.P. Grooteman, M.L. Bots, and et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents PLoS One 7 2012 e39783
18. J.J. Kroot, H. Tjalsma, R.E. Fleming, and et al. Hepcidin in human iron disorders: diagnostic implications Clin Chem 57 2011 1650 1669
19. J.J. Kroot, A.E. van Herwaarden, H. Tjalsma, and et al. Second round robin for plasma hepcidin methods: first steps toward harmonization Am J Hematol 87 2012 977 983
20. I.C. Macdougall, J. Malyszko, R.C. Hider, and et al. Current status of the measurement of blood hepcidin levels in chronic kidney disease Clin J Am Soc Nephrol 5 2010 1681 1689
21. R. Gualdi, G. Casalgrandi, G. Montosi, and et al. Excess iron into hepatocytes is required for activation of collagen type I gene during experimental siderosis Gastroenterology 107 1994 1118 1124
22. A. Pietrangelo, G. Montosi, A. Totaro, and et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene N Engl J Med 341 1999 725 732
23. G.A. Ramm, and R.G. Ruddell Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis Semin Liver Dis 25 2005 433 449
24. C. Canavese, D. Bergamo, G. Ciccone, and et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients Kidney Int 65 2004 1091 1098
25. P. Ferrari, H. Kulkarni, S. Dheda, and et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease Clin J Am Soc Nephrol 6 2011 77 83
26. H. Ghoti, E.A. Rachmilewitz, R. Simon-Lopez, and et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron Eur J Haematol 89 2012 87 93
27. P. Arosio, M. Yokota, and J.W. Drysdale Characterization of serum ferritin in iron overload: possible identity to natural apoferritin Br J Haematol 36 1977 199 207
28. M.A. van Bokhoven, C.T. van Deursen, and D.W. Swinkels Diagnosis and management of hereditary haemochromatosis BMJ 342 2011 c7251
29. C. Hershko Pathogenesis and management of iron toxicity in thalassemia Ann N Y Acad Sci 1202 2010 1 9
30. Y. Gandon, D. Olivie, D. Guyader, and et al. Non-invasive assessment of hepatic iron stores by MRI Lancet 363 2004 357 362
31. T.G. St Pierre, P.R. Clark, W. Chua-anusorn, and et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance Blood 105 2005 855 861
32. G. Rostoker, M. Griuncelli, C. Loridon, and et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study Am J Med 125 2012 991 999.e1
33. European Association for the Study of the Liver EASL clinical practice guidelines for HFE hemochromatosis J Hepatol 53 2010 3 22
34. G.R. Bailie, M. Larkina, D.A. Goodkin, and et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS) Nephrol Dial Transplant 28 2013 2570 2579
35. D.M. Charytan, A.B. Pai, C.T. Chan, and et al. Considerations and challenges in defining optimal iron utilization in hemodialysis J Am Soc Nephrol 26 2015 1238 1247
36. J. Himmelfarb, P. Stenvinkel, T.A. Ikizler, and et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 2002 1524 1538
37. Z.A. Massy, P. Stenvinkel, and T.B. Drueke The role of oxidative stress in chronic kidney disease Semin Dial 22 2009 405 408
38. P.S. Tucker, V.J. Dalbo, T. Han, and et al. Clinical and research markers of oxidative stress in chronic kidney disease Biomarkers 18 2013 103 115
39. K.L. Kuo, S.C. Hung, Y.H. Wei, and et al. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients J Am Soc Nephrol 19 2008 1817 1826
40. D. Tovbin, D. Mazor, M. Vorobiov, and et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation Am J Kidney Dis 40 2002 1005 1012
41. A.B. Pai, A.V. Boyd, C.R. McQuade, and et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis Pharmacotherapy 27 2007 343 350
42. A. Martin-Malo, A. Merino, J. Carracedo, and et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session Nephrol Dial Transplant 27 2012 2465 2471
43. V.S. Kamanna, S.H. Ganji, S. Shelkovnikov, and et al. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration Am J Nephrol 35 2012 114 119
44. T.M. Rooyakkers, E.S. Stroes, M.P. Kooistra, and et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo Eur J Clin Invest 32 suppl 1 2002 9 16
45. J.L. Sullivan Iron in arterial plaque: modifiable risk factor for atherosclerosis Biochim Biophys Acta 1790 2009 718 723
46. L. Kautz, V. Gabayan, X. Wang, and et al. Testing the iron hypothesis in a mouse model of atherosclerosis Cell Rep 5 2013 1436 1442
47. K.L. Kuo, S.C. Hung, T.S. Lee, and et al. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD J Am Soc Nephrol 25 2014 2596 2606
48. K. Kalantar-Zadeh, D.L. Regidor, C.J. McAllister, and et al. Time-dependent associations between iron and mortality in hemodialysis patients J Am Soc Nephrol 16 2005 3070 3080
49. T. Drueke, V. Witko-Sarsat, Z. Massy, and et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease Circulation 106 2002 2212 2217
50. K.A. Reis, G. Guz, H. Ozdemir, and et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease Int Heart J 46 2005 255 264
51. K.L. Kuo, S.C. Hung, Y.P. Lin, and et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients PLoS One 7 2012 e50295
52. A.V. Kshirsagar, J.K. Freburger, A.R. Ellis, and et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients PLoS One 8 2013 e78930
53. R.E. Fleming, and P. Ponka Iron overload in human disease N Engl J Med 366 2012 348 359
54. X. Zhang, and B.H. Rovin Beyond anemia: hepcidin, monocytes and inflammation Biol Chem 394 2013 231 238
55. H. Drakesmith, and A.M. Prentice Hepcidin and the iron-infection axis Science 338 2012 768 772
56. E. Bachman, R. Feng, T. Travison, and et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis J Clin Endocrinol Metab 95 2010 4743 4747
57. Q. Yang, J. Jian, S. Katz, and et al. 17β-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site Endocrinology 153 2012 3170 3178
58. L. Kautz, G. Jung, E.V. Valore, and et al. Identification of erythroferrone as an erythroid regulator of iron metabolism Nat Genet 46 2014 678 684
59. L. Valenti, P. Dongiovanni, B.M. Motta, and et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations Arterioscler Thromb Vasc Biol 31 2011 683 690
60. T.E. Galesloot, S. Holewijn, L.A. Kiemeney, and et al. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population Arterioscler Thromb Vasc Biol 34 2014 446 456
61. O. Saeed, F. Otsuka, R. Polavarapu, and et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis Arterioscler Thromb Vasc Biol 32 2012 299 307
62. T. Kuragano, K. Itoh, Y. Shimonaka, and et al. Hepcidin as well as TNF-alpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis Nephrol Dial Transplant 26 2011 2663 2667
63. N.C. van der Weerd, M.P. Grooteman, M.L. Bots, and et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients Nephrol Dial Transplant 28 2013 3062 3071
64. S. Fishbane, A. Mathew, and N.D. Vaziri Iron toxicity: relevance for dialysis patients Nephrol Dial Transplant 29 2014 255 259
65. J.T. Salonen, K. Nyyssonen, H. Korpela, and et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men Circulation 86 1992 803 811
66. L. Valenti, D.W. Swinkels, L. Burdick, and et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease Nutr Metab Cardiovasc Dis 21 2011 568 575
67. K. Kalantar-Zadeh, C.J. McAllister, R.S. Lehn, and et al. A low serum iron level is a predictor of poor outcome in hemodialysis patients Am J Kidney Dis 43 2004 671 684
68. J.M. Roob, G. Khoschsorur, A. Tiran, and et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis J Am Soc Nephrol 11 2000 539 549
69. G. Swarnalatha, R. Ram, P. Neela, and et al. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress Saudi J Kidney Dis Transpl 21 2010 852 858
70. T.A. Conner, C. McQuade, J. Olp, and et al. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose Biometals 25 2012 961 969
71. J. Himmelfarb, T.A. Ikizler, C. Ellis, and et al. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial J Am Soc Nephrol 25 2014 623 633
72. J. Wang, and K. Pantopoulos Regulation of cellular iron metabolism Biochem J 434 2011 365 381
73. M.W. Hentze, M.U. Muckenthaler, B. Galy, and et al. Two to tango: regulation of mammalian iron metabolism Cell 142 2010 24 38
74. E.D. Weinberg Iron availability and infection Biochim Biophys Acta 1790 2009 600 605
75. M. Nairz, A. Schroll, T. Sonnweber, and et al. The struggle for iron - a metal at the host-pathogen interface Cell Microbiol 12 2010 1691 1702
76. G. Weiss, and G. Schett Anaemia in inflammatory rheumatic diseases Nat Rev Rheumatol 9 2013 205 215
77. T. Ganz Iron in innate immunity: starve the invaders Curr Opin Immunol 21 2009 63 67
78. J.H. Ishida, and K.L. Johansen Iron and infection in hemodialysis patients Semin Dial 27 2014 26 36
79. A. Besarab, N. Amin, M. Ahsan, and et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients J Am Soc Nephrol 11 2000 530 538
80. D.W. Coyne, T. Kapoian, W. Suki, and et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J Am Soc Nephrol 18 2007 975 984
81. T. Kapoian, N.B. O'Mara, A.K. Singh, and et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin J Am Soc Nephrol 19 2008 372 379
82. G. Sirken, R. Raja, and A.R. Rizkala Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients Clin Nephrol 66 2006 348 356
83. C.J. Diskin, T.J. Stokes, L.M. Dansby, and et al. Is systemic heparin a risk factor for catheter-related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk factors Nephron Clin Pract 107 2007 c128 c132
84. M.A. Brookhart, J.K. Freburger, A.R. Ellis, and et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients J Am Soc Nephrol 24 2013 1151 1158
85. T. Kuragano, O. Matsumura, A. Matsuda, and et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients Kidney Int 86 2014 845 854
86. G.R. Bailie, M. Larkina, D.A. Goodkin, and et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality Kidney Int 87 2015 162 168
87. N. Tangri, D.C. Miskulin, J. Zhou, and et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study Nephrol Dial Transplant 30 2015 667 675
88. E. Zitt, G. Sturm, F. Kronenberg, and et al. Iron supplementation and mortality in incident dialysis patients: an observational study PLoS One 9 2014 e114144
89. P. Susantitaphong, F. Alqahtani, and B.L. Jaber Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis Am J Nephrol 39 2014 130 141
90. E. Litton, J. Xiao, and K.M. Ho Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials BMJ 347 2013 f4822
91. M. Muñoz, M. Auerbach, and A. Shander Re: Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials BMJ 13 September 2013 Available at: http://www.bmj.com/content/347/bmj.f4822/rr/661826 Accessed 17 September 2015
92. S. Prakash, A. Walele, N. Dimkovic, and et al. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients Perit Dial Int 21 2001 290 295
93. R. Agarwal, J.W. Kusek, and M.K. Pappas A randomized trial of intravenous and oral iron in chronic kidney disease Kidney Int 88 2015 905 914
94. I.C. Macdougall, A.H. Bock, F. Carrera, and et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia Nephrol Dial Transplant 29 2014 2075 2084
95. S. Chaplin, and S. Bhandari Oral iron: properties and current place in the treatment of anaemia Prescriber 23 2012 12 18
96. M. de Barrio, V. Fuentes, P. Tornero, and et al. Anaphylaxis to oral iron salts. Desensitization protocol for tolerance induction J Investig Allergol Clin Immunol 18 2008 305 308
97. C.W. Heath, M.B. Strauss, and W.B. Castle Quantitative aspects of iron deficiency in hypochromic anemia: the parenteral administration of iron J Clin Invest 11 1932 1293 1312
98. M. Auerbach, W. Strauss, S. Auerbach, and et al. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min Am J Hematol 88 2013 944 947
99. I.C. Macdougall Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 26 2010 473 482
100. J.E. Onken, D.B. Bregman, R.A. Harrington, and et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial Nephrol Dial Transplant 29 2014 833 842
101. B. Wikstrom, S. Bhandari, P. Barany, and et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease J Nephrol 24 2011 589 596
102. K.A. Moniem, and S. Bhandari Tolerability and efficacy of parenteral iron therapy in hemodialysis patients Trans Alt Trans Med 9 2007 37 42
103. FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). US Food and Drug Administration, Drug Safety Communications. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM440336.pdf. Accessed 18 May 2015.
104. S.N. Fishbane, A.K. Singh, S.H. Cournoyer, and et al. Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients [e-pub ahead of print] Nephrol Dial Transplant 13 July 2015 10.1093/ndt/gfv277
105. K. Yokoyama, H. Hirakata, T. Akiba, and et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD Clin J Am Soc Nephrol 9 2014 543 552
106. K.A. Barraclough, F. Brown, C.M. Hawley, and et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial Nephrol Dial Transplant 27 2012 4146 4153
107. M. Auerbach, H. Ballard, and J. Glaspy Clinical update: intravenous iron for anaemia Lancet 369 2007 1502 1504
108. C. Charytan, M.H. Schwenk, M.M. Al-Saloum, and et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products Nephron Clin Pract 96 2004 c63 c66
109. EU Clinical Trials Register. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB. Accessed 18 May 2015.
110. P. Stenvinkel, J.J. Carrero, J. Axelsson, and et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3 2008 505 521
111. J.J. Li, X. Meng, H.P. Si, and et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis Arterioscler Thromb Vasc Biol 32 2012 1158 1166
112. J. Ring, M. Grosber, M. Mohrenschlager, and et al. Anaphylaxis: acute treatment and management Chem Immunol Allergy 95 2010 201 210
113. J.W. Eschbach, J.D. Cook, and C.A. Finch Iron absorption in chronic renal disease Clin Sci 38 1970 191 196
114. M.P. Kooistra, and J.J. Marx The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients Nephrol Dial Transplant 13 1998 2578 2582
115. M.P. Kooistra, E.C. Niemantsverdriet, A. van Es, and et al. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium Nephrol Dial Transplant 13 1998 82 88
116. S. Fishbane, V.D. Ungureanu, J.K. Maesaka, and et al. The safety of intravenous iron dextran in hemodialysis patients Am J Kidney Dis 28 1996 529 534
117. B.P. Esposito, W. Breuer, I. Slotki, and et al. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients Eur J Clin Invest 32 suppl 1 2002 42 49
118. D. Van Wyck, J. Anderson, and K. Johnson Labile iron in parenteral iron formulations: a quantitative and comparative study Nephrol Dial Transplant 19 2004 561 565
119. H. Atalay, Y. Solak, K. Acar, and et al. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients Hemodial Int 15 2011 374 378
120. J.C. Barton, E.H. Barton, L.F. Bertoli, and et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation Am J Med 109 2000 27 32
121. European Medicines Agency. Procedure no. EMEA/H/A-31/1322, September 2013.
122. S.D. Anker, J. Comin Colet, G. Filippatos, and et al. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2009 2436 2448
123. T. Viethen, F. Gerhardt, D. Dumitrescu, and et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study Int J Cardiol 175 2014 233 239
124. L.M. Trotti, S. Bhadriraju, and L.A. Becker Iron for restless legs syndrome Cochrane Database Syst Rev 5 2012 CD007834
125. T. Mehmood, M. Auerbach, C.J. Earley, and et al. Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease) Sleep Med 15 2014 1473 1476
126. B. Favrat, K. Balck, C. Breymann, and et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women - PREFER a randomized, placebo-controlled study PLoS One 9 2014 e94217
127. P.A. Krayenbuehl, E. Battegay, C. Breymann, and et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration Blood 118 2011 3222 3227
128. K. Niihata, N. Tomosugi, T. Uehata, and et al. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease Nephrol Dial Transplant 27 2012 4378 4385
129. A.B. Pai, T. Conner, C.R. McQuade, and et al. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose Biometals 24 2011 603 613
130. B.G. Danielson Structure, chemistry, and pharmacokinetics of intravenous iron agents J Am Soc Nephrol 15 suppl 2 2004 S93 S98
131. J. Ring, and K. Messmer Incidence and severity of anaphylactoid reactions to colloid volume substitutes Lancet 1 1977 466 469